RESUMO
It has been suggested that immune-inï¬ammatory processes might be involved in the etiopathogenesis of schizophrenia. Since growing evidence indicates that adipokines strongly modulate the course of immune response and inflammatory processes, it is currently suggested the contribution of those factors in the etiology of schizophrenia as well. The aim of this study was to determine the serum levels of 4 adipokines-apelin, resistin, chemerin, and omentin-in patients with schizophrenia as compared with healthy subjects. Fifty-seven adult patients with schizophrenia and 31 healthy volunteers were included in this prospective study. ELISA was used to measure the serum concentration of resistin, apelin, omentin-1, and chemerin. No difference in the mean concentration of resistin (p=0.20) and chemerin (p=0.30) between patients with schizophrenia and the healthy group was observed. Apelin concentration was significantly (p=0.004) lower in patients with schizophrenia as compared with controls. A significant difference in apelin level between men with schizophrenia and control group (p=0.04) was reported. Apelin concentration was significantly correlated with waist-to-hip ratio, whereas chemerin concentration was significantly correlated with the Positive and Negative Syndrome Scale G score. There exists evidence that apelin might be involved in the pathogenesis of schizophrenia.
Assuntos
Apelina/sangue , Quimiocinas/sangue , Resistina/sangue , Esquizofrenia Paranoide/sangue , Adolescente , Adulto , Análise Química do Sangue , Composição Corporal , Estudos de Casos e Controles , Citocinas/sangue , Feminino , Proteínas Ligadas por GPI/sangue , Voluntários Saudáveis , Humanos , Lectinas/sangue , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Valores de Referência , Adulto JovemRESUMO
AIM: To evaluate clinical and biological efficacy and safety of electroconvulsive therapy (ECT) in patients with treatment-resistant paranoid schizophrenia. MATERIAL AND METHODS: Determination of CNS specific biological markers (BDNF, NSE, S100B), together with markers of inflammation and CNS alteration (IL-2, CPK, CPK-MB), and clinical evaluation were performed in two groups of patients: the ECT + antipsychotic treatment group (n=66) and the antipsychotic treatment group (n=32). RESULTS AND CONCLUSION: In the ECT + antipsychotic treatment group, the more pronounced reduction of psychotic symptoms has been revealed compared with subjects on antipsychotic treatment as monotherapy. Patients receiving ECT showed no increase in plasma levels of inflammation and CNS alteration biomarkers (NSE, S100B, CPK, CPK-MB, IL-2). The plasma level of BDNF, capable to characterize both the efficacy and safety of antipsychotic therapy, had a more pronounced upward trend in subjects with combined electroconvulsive and antipsychotic treatment, which may indicate good tolerability and high effectiveness of ECT.
Assuntos
Antipsicóticos , Biomarcadores , Eletroconvulsoterapia , Esquizofrenia Paranoide , Antipsicóticos/uso terapêutico , Biomarcadores/sangue , Humanos , Transtornos Psicóticos , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/terapia , Resultado do TratamentoRESUMO
Brain-derived neurotrophic factor (BDNF) has been implicated in the pathogenesis of psychiatric disorders. Schizophrenia is associated with metabolic abnormalities and BDNF regulates energy homeostasis and glucose metabolism in peripheral tissues. The aim of this study was to examine serum levels of BDNF in schizophrenic women during 8 weeks of treatment and control group, and its correlation with clinical and metabolic parameters. The study was performed on a group of 96 women: 55 diagnosed with paranoid schizophrenia according to DSM-IV criteria, and 41 healthy controls. Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of schizophrenia. BDNF serum levels and metabolic parameters: fasting serum glucose, total cholesterol, triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) were measured at baseline and week 8 of treatment. BDNF serum levels were significantly elevated in medicated patients with schizophrenia comparing to controls. After 8 weeks of antipsychotic treatment, BDNF levels did not significantly change. Increase in TG and TG/HDL-C ratio and a decrease in HDL-C was detected in medicated patients. Correlation between BDNF and lipid profile as well as symptoms severity was found. In our study we detected abnormalities in BDNF levels and lipid profile in medicated schizophrenic women in Polish population.
Assuntos
Glicemia/análise , Fator Neurotrófico Derivado do Encéfalo/sangue , Colesterol/sangue , Lipídeos/sangue , Esquizofrenia Paranoide/sangue , Doença Aguda , Adulto , Antipsicóticos/uso terapêutico , Biomarcadores/sangue , Feminino , Humanos , Polônia , Esquizofrenia Paranoide/tratamento farmacológico , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
The aim of this study was to search for correlates of cognitive impairment in patients with paranoid schizophrenia among clinical, demographic, anamnestic and biochemical markers (NSE, S100B protein, BDNF, hs-CRP). Patients with paranoid schizophrenia (n=125) were examined using the Brief Assessment of Cognitive Function in Schizophrenia, the Rey-Osterrieth Complex Figure task, and a number of clinical scales including the Positive and Negative Syndrome Scale. The majority of patients demonstrated cognitive impairment. The type of impairment was highly heterogeneous and individual. Relationships were found between the degree of executive functioning and family history of mental illness; working memory and age of onset of schizophrenia; and visual memory and psychopathological symptomatology. Negative and affective symptoms were not significantly associated with cognitive functioning. Treatment with first generation antipsychotics was associated with a more frequent impairment of motor skills, and concomitant anticholinergic drugs, with reduced accuracy. Use of second-generation antipsychotics only was associated with better accuracy, working memory and speech fluency. Among the patients, 21.4% had signs of a systemic inflammatory response, indicating a possible role of inflammatory response in the development of schizophrenia. CRP, S100B and NSE levels reflected features of the course of illness and therapeutic response. Patients with lower concentrations of BDNF were characterized by lower processing speeds.
Assuntos
Antipsicóticos/farmacologia , Disfunção Cognitiva/fisiopatologia , Função Executiva/fisiologia , Inflamação/sangue , Memória de Curto Prazo/fisiologia , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/fisiopatologia , Adulto , Disfunção Cognitiva/tratamento farmacológico , Disfunção Cognitiva/etiologia , Função Executiva/efeitos dos fármacos , Feminino , Humanos , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Pessoa de Meia-Idade , Esquizofrenia Paranoide/complicações , Esquizofrenia Paranoide/tratamento farmacológicoRESUMO
AIM: To assess the risk of thrombotic events in patients with schizophrenia and schizoaffective disorder based on 'fibrinodynamics' technology. MATERIAL AND METHODS: A group of 76 women, including 38 with paranoid schizophrenia (F20.0), 18 with schizoaffective disorder (F25.1) in the acute stage, and 20 healthy controls, participated in the study. The technology includes the study of coagulation and fibrinolysis, Karmin author software, and calculation of peak time and hemostasis potential of spontaneous clots. Growth and lysis of fibrin clots were studied in plasma purified from platelets. All preanalytic procedures were conducted within 30 minutes after blood sampling. Blood serum was studied separately using the neuroimmunological test. Dynamic of brightness profiles of the clots was determined and a number of parameters (peak time and hemostasis potential of spontaneous clots) were calculated using the Karmin software. RESULTS: In patients with schizophrenia, the dynamic brightness profile of the clots has two peaks: the first peak is formed as a result of the growth and lysis of the clot initiated by the activator, the second peak is due to the growth and lysis of spontaneous clots in the volume of the measuring cuvette far from the activator. In healthy donors, the second peak under experimental conditions is absent. In the group of schizophrenic patients, a strong negative correlation is observed between the peak time of the second peak and the activity of leukocyte elastase (Spearman R = -0.75, p<0.0001), i.e. the greater the activity of elastase, the earlier the maximum of the second peak is formed and vice versa. In the control group, there is no such correlation. Evaluation of the potential of hemostasis of spontaneous clots showed that in 42% of schizophrenic patients this parameter is shifted above the norm, which indicates an increased risk of thrombosis of small brain arteries in these patients. CONCLUSION: The developed technology of 'fibrinodynamics' has a good potential for introduction into personalized medicine to identify increased risks of thrombosis of small cerebral vessels in patients with acute schizophrenia leading to the development of cognitive disorders and to control the normalization of hemostasis with antiplatelet or anticoagulant drugs.
Assuntos
Fibrina/análise , Transtornos Psicóticos/sangue , Esquizofrenia Paranoide/sangue , Trombose/diagnóstico , Adulto , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Coagulação Sanguínea/efeitos dos fármacos , Plaquetas/efeitos dos fármacos , Feminino , Fibrinólise , Hemostasia/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Transtornos Psicóticos/complicações , Medição de Risco , Esquizofrenia Paranoide/complicações , Software , Trombose/complicações , Trombose/prevenção & controleRESUMO
Free radicals and an oxidant/antioxidant imbalance have been involved in the schizophrenia pathophysiology. The total antioxidant capacity (TAC) is a measure of the antioxidant capacity of a system. Day/night changes are a biological characteristic of hormones such as melatonin or cortisol. There is little information about TAC day/night changes in schizophrenia patients. The aim of this research is to study if there are day/night changes in serum TAC levels of schizophrenia patients. Thirty-two DSM-IV schizophrenia paranoid patients were studied. Blood was sampled at 12:00 and 00:00 h at admission, discharge and three months after hospital discharge (TMAHD). TAC results are expressed as mmol of Trolox/L. Patients did not have day/night TAC differences at admission (12:00: 0.67±0.12 vs. 00:00: 0.61±0.14, p>0.14) or discharge (12:00: 0.65±0.15 vs. 00:00: 0.65±0.12, p>0.99). At TMHD, patients had significantly higher TAC levels at midday than midnight (12:00: 0.83±0.10 vs. 00:00: 0.74±0.12, p<0.006) as it has been reported in healthy subjects. There were no significant TAC differences at 12.00 and 00:00 between admission and discharge. At TMAHD, patients had significantly higher TAC levels than at admission and discharge, both at 12:00 and 00:00 h. In conclusion, the absence of day/night serum TAC changes when clinically relapsed and the normalization of day/night serum TAC changes at TMHD can be considered as a biological marker of schizophrenia evolution.
Assuntos
Antioxidantes/metabolismo , Esquizofrenia Paranoide/sangue , Adulto , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Admissão do PacienteRESUMO
There are day/night and seasonal changes in biological markers such as melatonin and cortisol. Controversial changes in serum S100B protein levels have been described in schizophrenia. We aim studying whether serum S100B levels present day/night variations in schizophrenia patients and whether S100B levels are related to psychopathology. Sixty-five paranoid schizophrenic inpatients participated in the study. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and discharge. Blood was drawn at 12:00 (midday) and 00:00 (midnight) hours at admission and discharge. Sixty-five healthy subjects matched by age, gender and season acted as control group. At admission and discharge patients had significantly higher serum S100B concentrations at midday and midnight than healthy subjects. At admission, patients showed a day/night variation of S100B levels, with higher S100B levels at 12:00 than at 00:00h (143.7±26.3pg/ml vs. 96.9±16.6pg/ml). This day/night difference was not present in the control group. Midday and midnight S100B at admission decreased when compared to S100B at discharge (midday, 143.7±26.3 vs. 83.0±12, midnight 96.9±16.6 vs. 68.6±14.5). There was a positive correlation between the PANSS positive subscale and S100B concentrations at admission. This correlation was not present at discharge. CONCLUSIONS: acute paranoid schizophrenia inpatients present a day/night change of S100B serum levels at admission that disappears at discharge. The correlation between serum S100B concentrations and the PANSS positive scores at admission as well as the decrease of S100B at discharge may be interpreted as an acute biological response to the clinical state of the patients.
Assuntos
Ritmo Circadiano/fisiologia , Subunidade beta da Proteína Ligante de Cálcio S100/sangue , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/fisiopatologia , Doença Aguda , Adulto , Análise de Variância , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação PsiquiátricaRESUMO
BACKGROUND: An oxidant-antioxidant system dysregulation has been described as a schizophrenia pathophysiological base. The total antioxidant capacity (TAC) is one measure of the antioxidant capacity of a system. Day/night concentration changes is a biological characteristic of hormones such as melatonin or cortisol. There is no information about TAC day/night changes in schizophrenia. AIMS: Studying the existence of a day/night TAC change in schizophrenia. METHOD: Forty-three DSM-IV paranoid schizophrenia inpatients participated in the study. Thirty healthy subjects matched by age and gender acted as control group. Blood was sampled at 12:00 and 00:00h the day after admission and the day before discharge. Serum TAC was measured by the ABTS radical cation technique and expressed in Trolox mmol/L. RESULTS: Patients had significantly lower TAC levels at admission and discharge (12:00 and 00:00) than controls. At admission patients had a TAC day/night change, with higher day-time than night-time levels (0.66±0.14 vs 0.60±0.15) as well as healthy subjects (0.83±0.07 vs 0.77±0.11). At discharge patients had a similar TAC level at 12:00 and 00:00 (0.64±0.15 vs 0.63±0.14). CONCLUSION: Schizophrenic patients present a deficit of the antioxidant system. The initial presence and the later absence of a day/night change deserves future studies.
Assuntos
Antioxidantes , Estresse Oxidativo/fisiologia , Esquizofrenia Paranoide/diagnóstico , Adulto , Biomarcadores/sangue , Doença Crônica , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva , Esquizofrenia Paranoide/sangueAssuntos
Antipsicóticos/efeitos adversos , Clozapina/efeitos adversos , Antígenos HLA/sangue , Teste de Histocompatibilidade , Neutropenia/induzido quimicamente , Esquizofrenia Paranoide/tratamento farmacológico , Adulto , Antipsicóticos/administração & dosagem , Clozapina/administração & dosagem , Feminino , Humanos , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/imunologiaRESUMO
Oxidative DNA damage has been proposed as one of the causes of schizophrenia (SZ), and post mortem data indicate a dysregulation of apoptosis in SZ patients. To evaluate apoptosis in vivo we quantified the concentration of plasma cell-free DNA (cfDNA index, determined using fluorescence), the levels of 8-oxodG in cfDNA (immunoassay) and lymphocytes (FL1-8-oxodG index, flow cytometry) of male patients with acute psychotic disorders: paranoid SZ (total N = 58), schizophreniform (N = 11) and alcohol-induced (N = 14) psychotic disorder, and 30 healthy males. CfDNA in SZ (N = 58) does not change compared with controls. In SZ patients. Elevated levels of 8-oxodG were found in cfDNA (N = 58) and lymphocytes (n = 45). The main sources of cfDNA are dying cells with oxidized DNA. Thus, the cfDNA/FL1-8-oxodG ratio shows the level of apoptosis in damaged cells. Two subgroups were identified among the SZ patients (n = 45). For SZ-1 (31%) and SZ-2 (69%) median values of cfDNA/FL1-8-oxodG index are related as 1:6 (p < 0.0000001). For the patients with other psychotic disorders and healthy controls, cfDNA/FL1-8-oxodG values were within the range of the values in SZ-2. Thus, apoptosis is impaired in approximately one-third of SZ patients. This leads to an increase in the number of cells with damaged DNA in the patient's body tissues and may be a contributing cause of acute psychotic disorder.
Assuntos
Apoptose , Dano ao DNA , DNA/sangue , Linfócitos/patologia , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/patologia , 8-Hidroxi-2'-Desoxiguanosina , Adulto , Transtornos Induzidos por Álcool/sangue , Transtornos Induzidos por Álcool/patologia , Nucleotídeos de Desoxiguanina/metabolismo , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Feminino , Citometria de Fluxo , Humanos , Linfócitos/metabolismo , Masculino , Escalas de Graduação Psiquiátrica , Transtornos Psicóticos/sangue , Transtornos Psicóticos/patologia , Piranos , Esquizofrenia , Estatísticas não ParamétricasRESUMO
OBJECTIVE: While doctors often increase the dose of an antipsychotic when there is insufficient response, there is limited evidence that this intervention is any better than waiting longer on the lower dose. We put the proposition to test. METHOD: In this 4-week, double-blind, randomized controlled trial conducted in psychiatric care from September 2012 to March 2015, 103 patients with schizophrenia (ICD-10) who did not respond to olanzapine 10 mg/d or risperidone 3 mg/d were randomly allocated to a dose-increment or -continuation group. In the increment group, antipsychotic doses were doubled for 4 weeks, whereas in the continuation group, doses were not changed. Completion rate (primary outcome measure); changes in psychopathology, function, and extrapyramidal symptoms; and response rate were compared between the groups. The relationship between baseline plasma antipsychotic concentrations and changes in psychopathology was examined. RESULTS: The completion rate was significantly lower in the increment group than in the continuation group (69.2% [36/52] vs 86.3% [44/51], P = .038). No significant superiority was observed in any of the outcome measures in the increment group compared to the continuation group, except the Positive and Negative Syndrome Scale (PANSS) positive subscale score change in intention-to-treat analysis. Those with lower plasma concentrations of olanzapine on their initial treatment showed a greater improvement on the PANSS positive subscale when their dose was increased (P = .042). CONCLUSIONS: As a general strategy, patients with schizophrenia failing to respond to moderate antipsychotic doses may not benefit from an increase in dose. The possibility of benefit in those whose plasma antipsychotic concentrations at baseline are still low cannot be ruled out. TRIAL REGISTRATION: UMIN.ac.jp/ctr/index.htm identifier: UMIN000008667.
Assuntos
Benzodiazepinas/administração & dosagem , Transtornos Psicóticos/tratamento farmacológico , Risperidona/administração & dosagem , Esquizofrenia Paranoide/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Adulto , Idoso , Benzodiazepinas/efeitos adversos , Benzodiazepinas/farmacocinética , Relação Dose-Resposta a Droga , Método Duplo-Cego , Resistência a Medicamentos , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Olanzapina , Escalas de Graduação Psiquiátrica , Transtornos Psicóticos/sangue , Transtornos Psicóticos/diagnóstico , Risperidona/efeitos adversos , Risperidona/farmacocinética , Esquizofrenia/sangue , Esquizofrenia/diagnóstico , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/diagnósticoRESUMO
OBJECTIVE: The current study determined the ability of a 51-analyte immunoassay panel to discriminate between subjects with chronic schizophrenia and healthy control subjects in an American population. METHODS: Serum samples were collected from 25 subjects with a DSM-IV-TR diagnosis of schizophrenia and 50 healthy control subjects. Blinded samples were sent to the RulesBaseMedicine (RBM) laboratory, which analyzed the 51 biomarkers and converted the results into the VeriPsych score by the application of RBM-determined decision rules and returned these scores to the investigators. The VeriPsych score yields a conditional probability ranging from strongly positive to strongly negative that the sample was from someone who had schizophrenia. Sensitivity and specificity were calculated for these data. The study was conducted between February 27, 2010, and August 31, 2011. RESULTS: On the basis of this test, the conditional probability of having schizophrenia ranged from 35% to 98% in the subjects previously diagnosed with schizophrenia and ranged from < 12% to 99% in the healthy control subjects. The sensitivity of this 51-plex biomarker was 89% in this study, while the specificity was 34%. CONCLUSIONS: The current study confirms that the 51-plex test performs as expected in individuals with chronic schizophrenia (sensitivity = 89%), indicating that the abnormalities in this multiple biomarker test persist and are not affected by the number of years this illness has been present or by its treatment. However, there was a high false-positive rate in healthy control subjects in our sample, leading to a low specificity rate of 34%. Due to the high false-positive rate in our normal controls, this biomarker test was not able to discriminate between healthy control subjects and subjects with chronic schizophrenia in our sample.
Assuntos
Biomarcadores/sangue , Imunoensaio/estatística & dados numéricos , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/diagnóstico , Adolescente , Adulto , Estudos de Casos e Controles , Reações Falso-Positivas , Feminino , Humanos , Masculino , Probabilidade , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Psicometria/estatística & dados numéricos , Valores de Referência , Esquizofrenia Paranoide/psicologia , Adulto JovemRESUMO
OBJECTIVE: To study correlations between parameters of lipid metabolism and ECG in patients with schizophrenia in light of therapy with atypical antipsychotics. MATERIAL AND METHODS: We examined 42 patients with paranoid schizophrenia. All patients received atypical neuroleptics - seroquel, zyprexa, and rispolept. A group of controls included 25 healthy people. RESULTS: There was a significant increase (p=0.0002) in body mass (in average by 1.5 kg) in 88% patients. A significant increase in the concentration of serum triglycerides was identified as well. The concentration of VLDL in the patients with schizophrenia was 2 times higher compared to controls. After treatment, VLDL concentration increased even more considerably An increase in atherogenic index (AI) was up to 3.1 in patients with schizophrenia compared to 2.2 in controls. After treatment, Al increased up to 4 that demonstrated the high risk of development of atherosclerosis. A significant increase in QT interval in the ECG and heart rate (p=0.03) was revealed only in patients receiving rispolept. In patients receiving zyprexa and seroquel only heart rate was increased. CONCLUSION: The antipsychotics studied increase the risk of development of cardiovascular pathology.
Assuntos
Antipsicóticos/efeitos adversos , Aterosclerose/induzido quimicamente , Benzodiazepinas/efeitos adversos , Dibenzotiazepinas/efeitos adversos , Metabolismo dos Lipídeos/efeitos dos fármacos , Risperidona/efeitos adversos , Esquizofrenia Paranoide/tratamento farmacológico , Adulto , Antipsicóticos/uso terapêutico , Aterosclerose/sangue , Benzodiazepinas/uso terapêutico , Dibenzotiazepinas/uso terapêutico , Eletrocardiografia , Feminino , Humanos , Lipoproteínas VLDL/sangue , Masculino , Pessoa de Meia-Idade , Olanzapina , Fumarato de Quetiapina , Risperidona/uso terapêutico , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/fisiopatologia , Aumento de Peso , Adulto JovemAssuntos
Antipsicóticos/sangue , Clozapina/sangue , Monitorização Fisiológica/métodos , Palmitato de Paliperidona/sangue , Diálise Renal/métodos , Esquizofrenia Paranoide/terapia , Antipsicóticos/uso terapêutico , Clozapina/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Palmitato de Paliperidona/uso terapêutico , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/complicações , Fumar/sangueAssuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Rabdomiólise/induzido quimicamente , Esquizofrenia Paranoide/tratamento farmacológico , Adulto , Antipsicóticos/administração & dosagem , Creatina Quinase/análise , Creatina Quinase/sangue , Humanos , Masculino , Rabdomiólise/sangue , Rabdomiólise/diagnóstico , Esquizofrenia Paranoide/sangueRESUMO
We studied 73 patients with paranoid schizophrenia with resistance to neuroleptics. All patients were divided into two groups - basic (37 patients) and comparison (36 patients). Both groups received traditional treatment. Patients of the basic group were treated with the combination of reamberin and cycloferon. Before treatment, significant alterations in the interferon status (IFS), which were characterized by the decrease of serum interferon (SIFN) activity and blood α- and γ-interferons (IFN) levels, were identified in both group. The positive effect of the drug combination on clinical symptoms and interferon status (the normalization of SIFN activity, increase in blood α- and γ-IFN levels) was found.
Assuntos
Acridinas/uso terapêutico , Resistência a Medicamentos , Indutores de Interferon/uso terapêutico , Interferon-alfa/imunologia , Interferon gama/imunologia , Meglumina/análogos & derivados , Esquizofrenia Paranoide/tratamento farmacológico , Succinatos/uso terapêutico , Adulto , Antipsicóticos/uso terapêutico , Quimioterapia Combinada , Humanos , Interferon-alfa/sangue , Interferon gama/sangue , Meglumina/uso terapêutico , Pessoa de Meia-Idade , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/imunologia , Adulto JovemRESUMO
Atypical antipsychotic drugs, such as olanzapine, have been shown to alleviate the positive, negative and, to a lesser degree, the cognitive symptoms of schizophrenia in many patients. However, the detailed mechanisms of action of these drugs have yet to be elucidated. We have carried out the first investigation aimed at evaluating the effects of olanzapine treatment on the glycosylation of serum proteins in schizophrenia patients. Olanzapine treatment resulted in increased levels of a disialylated biantennary glycan and reduced levels of a number of disialylated bi- and triantennary glycans on whole serum glycoproteins. These changes were not observed on a low-abundance serum protein fraction. α1 acid glycoprotein was identified as a carrier of some of the detected altered oligosaccharides. In addition, glycan analysis of haptoglobin, transferrin, and α1 antitrypsin reported similar findings, although these changes did not reach significance. Exoglycosidase digestion analysis showed that olanzapine treatment increased galactosylation and sialylation of whole serum proteins, suggesting increased activity of specific galactosyltransferases and increased availability of galactose residues for sialylation. Taken together, these findings indicate that olanzapine treatment results in altered glycosylation of serum proteins.
Assuntos
Antipsicóticos/farmacologia , Benzodiazepinas/farmacologia , Glicoproteínas/sangue , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Esquizofrenia Paranoide/sangue , Doença Aguda , Adulto , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Cromatografia Líquida , Feminino , Glicômica , Glicoproteínas/isolamento & purificação , Glicoproteínas/metabolismo , Glicosilação , Humanos , Interações Hidrofóbicas e Hidrofílicas , Masculino , Pessoa de Meia-Idade , Olanzapina , Orosomucoide/metabolismo , Polissacarídeos/sangue , Esquizofrenia Paranoide/tratamento farmacológico , Adulto Jovem , alfa 1-Antitripsina/sangueRESUMO
We report our experience with a 34-year-old patient with schizophrenia, paranoid subtype, who demonstrated an elevation of clozapine serum levels subsequent to pregabalin comedication used for the treatment of schizophrenic anxiety. This observation turned to be dose-dependent. Although the pharmacokinetic profile of pregabalin suggests an exclusive renal elimination, our report supports the presumption of a possible direct or indirect hepatic "effect" of pregabalin.
Assuntos
Ansiolíticos/efeitos adversos , Antipsicóticos/farmacocinética , Clozapina/farmacocinética , Quimioterapia Combinada/efeitos adversos , Esquizofrenia Paranoide/sangue , Ácido gama-Aminobutírico/análogos & derivados , Adulto , Ansiolíticos/administração & dosagem , Antipsicóticos/administração & dosagem , Clozapina/administração & dosagem , Relação Dose-Resposta a Droga , Humanos , Masculino , Pregabalina , Esquizofrenia Paranoide/tratamento farmacológico , Ácido gama-Aminobutírico/administração & dosagem , Ácido gama-Aminobutírico/efeitos adversosRESUMO
Several studies have provided evidence for increased S100B serum concentrations in schizophrenia. The pathophysiological significance of this finding is still uncertain because S100B is involved in many cellular mechanisms and is not astrocyte-specific as was previously assumed. S100B is also expressed by subsets of CD3+ CD8+ T cells and natural killer (NK) cells and may therefore be linked to the immune hypothesis of schizophrenia. We have quantified S100B+ CD3+ CD8+ T cells and NK cells by flow cytometry in the peripheral blood of 26 acutely ill schizophrenia cases and 32 matched controls. In parallel, S100B concentrations and the free cortisol index (FCI), a surrogate marker for stress axis activity, were determined in serum samples from the same blood draw. Psychopathology was monitored using the Positive and Negative Syndrome Scale (PANSS). The patient group had increased S100B+ NK cell counts (P=0.045), which correlated with the FCI (r=0.299, P=0.026) but not with the PANSS or the elevated (P=0.021) S100B serum concentrations. S100B+ CD3+ CD8+ T cell counts were not significantly changed in the patient group and did neither correlate with the FCI and PANSS, nor with S100B serum concentrations. In conclusion, despite the observation of an increase in S100B+ NK cells in schizophrenia patients, the lack of a correlation with serum S100B concentrations suggests that these cells are probably not a major source of S100B in the blood of schizophrenia patients. Notably, elevated S100B+ NK cell counts may be linked with stress axis activation.
Assuntos
Complexo CD3/imunologia , Linfócitos T CD8-Positivos/imunologia , Hidrocortisona/sangue , Células Matadoras Naturais/imunologia , Fatores de Crescimento Neural/imunologia , Proteínas S100/imunologia , Esquizofrenia Paranoide/imunologia , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Feminino , Citometria de Fluxo , Humanos , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Fatores de Crescimento Neural/sangue , Subunidade beta da Proteína Ligante de Cálcio S100 , Proteínas S100/sangue , Esquizofrenia Paranoide/sangue , Estresse Psicológico , Subpopulações de Linfócitos TRESUMO
It is believed that during mid-to-late gestation, docosahexaenoic acid (DHA), an n-3 fatty acid, plays an important role in fetal and infant brain development, including neurocognitive and neuromotor functions. Deficits in several such functions have been associated with schizophrenia. Though sufficient levels of DHA appear to be important in neurodevelopment, elevated maternal DHA levels have also been associated with abnormal reproductive outcomes in both animal models and humans. Our objective was to assess whether a disturbance in maternal DHA levels, measured prospectively during pregnancy, was associated with risk of schizophrenia and other schizophrenia spectrum disorders (SSD) in adult offspring. In order to test the hypothesis that abnormal levels of DHA are associated with SSD, a case-control study nested within a large, population-based birth cohort, born from 1959 through 1967 and followed up for SSD from 1981 through 1997, was utilized. Maternal levels of both DHA and arachidonic acid (AA), an n-6 fatty acid, were analyzed in archived maternal sera from 57 cases of SSD and 95 matched controls. There was a greater than twofold increased risk of SSD among subjects exposed to maternal serum DHA in the highest tertile (OR=2.38, 95% CI=1.19, 4.76, p=0.01); no such relationship was found between AA and SSD. These findings suggest that elevated maternal DHA is associated with increased risk for the development of SSD in offspring.